BR9915546A - Terapia de combinação de ribavirin- interferon alfa para a erradiação de hcv-rna detectável em pacientes tendo infecção por hepatite c crÈnica - Google Patents

Terapia de combinação de ribavirin- interferon alfa para a erradiação de hcv-rna detectável em pacientes tendo infecção por hepatite c crÈnica

Info

Publication number
BR9915546A
BR9915546A BR9915546-0A BR9915546A BR9915546A BR 9915546 A BR9915546 A BR 9915546A BR 9915546 A BR9915546 A BR 9915546A BR 9915546 A BR9915546 A BR 9915546A
Authority
BR
Brazil
Prior art keywords
infection
rna
ribavirin
combination therapy
chronic hepatitis
Prior art date
Application number
BR9915546-0A
Other languages
English (en)
Inventor
Ashit K Ganguly
Jinping Mccormick
Raymond G Lovey
Frank Bennett
Anil K Saksena
Viyyoor M Girijavallabhan
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/348,534 external-priority patent/US6277830B1/en
Application filed by Schering Corp filed Critical Schering Corp
Publication of BR9915546A publication Critical patent/BR9915546A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

Patente de Invenção: <B>"TERAPIA DE COMBINAçãO DE RIBAVIRIN- INTERFERON ALFA PARA A ERRADICAçãO DE HCV-RNA DETECTáVEL EM PACIENTES TENDO INFECçãO POR HEPATITE C CRÈNICA"<D>. Método para o tratamento de um paciente tendo infecção por hepatite C crónica para erradicar HCV-RNA detectável envolvendo uma terapia de combinação usando uma quantidade terapeuticamente eficaz de derivado de ribavirin da fórmula (I) e uma quantidade terapeuticamente eficaz de interferon alfa por um período de tempo de a partir de 20 até 80 semanas.
BR9915546-0A 1998-10-16 1999-10-14 Terapia de combinação de ribavirin- interferon alfa para a erradiação de hcv-rna detectável em pacientes tendo infecção por hepatite c crÈnica BR9915546A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17405998A 1998-10-16 1998-10-16
US09/348,534 US6277830B1 (en) 1998-10-16 1999-07-07 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
PCT/US1999/021448 WO2000023454A1 (en) 1998-10-16 1999-10-14 Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection

Publications (1)

Publication Number Publication Date
BR9915546A true BR9915546A (pt) 2001-08-14

Family

ID=26869824

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9915546-0A BR9915546A (pt) 1998-10-16 1999-10-14 Terapia de combinação de ribavirin- interferon alfa para a erradiação de hcv-rna detectável em pacientes tendo infecção por hepatite c crÈnica

Country Status (20)

Country Link
EP (1) EP1121369B1 (pt)
JP (1) JP2002527522A (pt)
CN (1) CN1330658A (pt)
AT (1) ATE284408T1 (pt)
AU (1) AU762395B2 (pt)
BR (1) BR9915546A (pt)
CA (1) CA2346447C (pt)
CZ (1) CZ20011130A3 (pt)
DE (1) DE69922529T2 (pt)
ES (1) ES2229820T3 (pt)
HU (1) HUP0200447A2 (pt)
ID (1) ID29187A (pt)
IL (1) IL142423A0 (pt)
NO (1) NO20011789L (pt)
NZ (1) NZ510811A (pt)
PL (1) PL347268A1 (pt)
RU (1) RU2001113268A (pt)
SK (1) SK4742001A3 (pt)
TR (1) TR200101085T2 (pt)
WO (1) WO2000023454A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1282632A1 (en) 2000-04-20 2003-02-12 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection
TWI332507B (en) 2002-11-19 2010-11-01 Hoffmann La Roche Antiviral nucleoside derivatives
RU2005133093A (ru) * 2003-03-28 2006-07-27 Фармассет, Инк. (Us) Соединения для лечения флавивирусных инфекций
WO2005016370A1 (en) * 2003-08-13 2005-02-24 Howard J. Smith & Associates Pty Ltd Method of treating viral infections
WO2005049065A2 (en) * 2003-11-19 2005-06-02 Rigel Pharmaceuticals, Inc. Synergistic combinations of dihaloacetamide with interferon or ribavirin for treatment hcv infections
CN101203498A (zh) 2005-05-02 2008-06-18 里格尔药品股份有限公司 包括可代谢部分的杂环抗病毒化合物及其用途
JPWO2009028573A1 (ja) 2007-08-27 2010-12-09 国立大学法人名古屋大学 血液凝固障害におけるリバビリンの利用
WO2009028575A1 (ja) 2007-08-27 2009-03-05 National University Corporation Nagoya University 血液凝固第vii因子プロモーターの活性化剤及びその利用
WO2011151667A1 (en) 2010-06-02 2011-12-08 Adbula Kurkayev Antiviral compositions
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
DE202012012954U1 (de) 2011-10-21 2014-08-12 Abbvie Inc. Eine Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen (DAAs) für die Verwendung zur Behandlung von HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
DK2583677T1 (da) 2011-10-21 2015-01-19 Abbvie Inc Fremgangsmåder til behandling af HCV omfattende mindst to direktevirkende antivirale midler, ribavirin, men ikke inteferon
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
US11981703B2 (en) 2016-08-17 2024-05-14 Sirius Therapeutics, Inc. Polynucleotide constructs
WO2019006455A1 (en) 2017-06-30 2019-01-03 Solstice Biologics, Ltd. AUXILIARIES OF CHIRAL PHOSPHORAMIDITIS AND METHODS OF USE THEREOF
CN107513055B (zh) * 2017-08-11 2018-06-22 广东昊邦医药健康有限责任公司 一种利巴韦林衍生化合物及其药物组合物
CN117355311A (zh) 2022-05-05 2024-01-05 阿卜杜拉·库尔卡耶夫 用于恢复生物体生理过程和细胞的药物组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1482736A (en) * 1974-03-18 1977-08-10 Icn Pharmaceuticals 1-(beta-d-ribofuranosyl)-1,2,4-triazole acid derivatives
US4544741A (en) * 1982-03-29 1985-10-01 Robins Roland K Azole dinucleotide compounds and methods for their production
US4925930A (en) * 1988-11-02 1990-05-15 Nucleic Acid Research Institute Synthesis and anti-leukemic activity of alkyl-1-(β-D-ribofuranosyl)[1,2,4]triazole-3-carboximidates
GB9307043D0 (en) * 1993-04-05 1993-05-26 Norsk Hydro As Chemical compounds
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
KR20000053226A (ko) * 1996-11-12 2000-08-25 요나스 프릭 뉴클레오사이드

Also Published As

Publication number Publication date
DE69922529T2 (de) 2005-12-15
NO20011789D0 (no) 2001-04-09
CA2346447C (en) 2006-01-31
CA2346447A1 (en) 2000-04-27
TR200101085T2 (tr) 2001-08-21
CZ20011130A3 (cs) 2001-08-15
NO20011789L (no) 2001-06-11
RU2001113268A (ru) 2003-09-27
ID29187A (id) 2001-08-09
NZ510811A (en) 2003-06-30
ATE284408T1 (de) 2004-12-15
WO2000023454A1 (en) 2000-04-27
CN1330658A (zh) 2002-01-09
IL142423A0 (en) 2002-03-10
HUP0200447A2 (en) 2002-06-29
DE69922529D1 (de) 2005-01-13
PL347268A1 (en) 2002-03-25
SK4742001A3 (en) 2001-11-06
EP1121369B1 (en) 2004-12-08
ES2229820T3 (es) 2005-04-16
AU1197500A (en) 2000-05-08
AU762395B2 (en) 2003-06-26
EP1121369A1 (en) 2001-08-08
JP2002527522A (ja) 2002-08-27

Similar Documents

Publication Publication Date Title
BR9910505A (pt) Terapia de combinação compreendendo ribavirina e interferon alfa em pacientes cândidos de tratamento antiviral tendo infecção crÈnica por hepatite c
BR9915546A (pt) Terapia de combinação de ribavirin- interferon alfa para a erradiação de hcv-rna detectável em pacientes tendo infecção por hepatite c crÈnica
BR9812484A (pt) Terapia combinada para erradicação de hcv-rna detectável em pacientes com infecção crÈnica por hepatite c
AR021226A1 (es) Terapia combinatoria con ribavirina-interferon alfa para erradicar el hcv-rna detectable en aquellos pacientes que presentan infeccion porhepatitis c cronica
BR9911076A (pt) Uso de peg-ifn-alfa e ribavirina para o tratamento de hepatite c crÈnica
WO2000037110A3 (en) Ribavirin-pegylated interferon alfa induction hcv combination therapy
BR0009840A (pt) Terapia de combinação para hcv, contendo ribavirina em associação com antioxidantes
BR9809425A (pt) Conjugados alfa interferon-polietilenoglicol para terapia de infecção
NO20025627D0 (no) Fremgangsmåter og sammensetninger for å behandle hepatitt C virus
BR9809678A (pt) Derivados de triptolìdeo úteis no tratamento de doenças autoimunes
AR022116A1 (es) Terapia de combinacion para el vhc por induccion de ribavirina - interferon alfa
BR0212917A (pt) Método para tratamento de infecção de vìrus da hepatite c em pacientes que não responderam a tratamento
BR0113115A (pt) Tratamento de hepatite c com timosina, interferon e ribavirina
ECSP993178A (es) Terapia combinatoria con ribarvirina -interferon alfa para erradicar el hcv - rna detectable en aquellos pacientes que presentan infeccion por hepatitis c cronica
ECSP982669A (es) Terapia en combinacion para erradicar vhc -arn detectable en pacientes que padecen infeccion de hetatitis c cronica
MX9708885A (es) Uso de ribavirin e interferon alfa para el tratamiento de hepatitis c.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1913 DE 04/09/2007.